Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 3812465 in Center-involved Diabetic Macular Edema
NCT07553429Phase 2Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- May 2026
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of BI 3812465 in diabetic macular edema (DME) (6 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Dose Limiting Events at 169 days and Ocular Adverse Events at 169 days. Started May 2026; status: recruiting.
02
Drugs
BI 3812465
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT07553429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07553429.